Table 1.
Baseline characteristics upon hospital admission and process measures.
| Overall | Propensity Score Matched | |||||
|---|---|---|---|---|---|---|
| BMT n = 133 | BMT + EVT n = 270 | p | BMT n = 73 | BMT + EVT n = 73 | p | |
| Age (years, mean, SD) | 73.4 ± 13.1 | 71.1 ± 12.9 | 0.06 | 69.86 (±13.2) | 68.3 (±13.3) | 0.485 |
| Female | 68 (51.1) | 114 (42.2) | 0.347 | 33 (45.2) | 31 (42.5) | 0.868 |
| NIHSS (median, IQR) | 8 (3–20) | 14 (7–22) | <0.001 | 6 (3–17) | 8 (4–18) | 0.255 |
| NIHSS <10 | 72 (54.1) | 94 (34.8) | <0.001 | 45 (61.6) | 37 (50.7) | 0.243 |
| NIHSS ≥ 10 | 61 (45.9) | 176 (65.2) | <0.001 | 28. (38.4) | 36 (49.3) | 0.243 |
| Need for care prior stroke | 0.008 | |||||
| - independent- care at home- institutional care | 100 (75.2) 11 (8.3) 22 (16.5) | 227 (84.1) 25 (9.3) 18 (6.7) | 100 (100) —- | 100 (100) – | – | |
| Admission to hospital | 0.218 | 0.776 | ||||
| - self-initiated- via family physician- via emergency service- secondary transfer | 3 (2.3) 4 (3.0) 95 (71.4) 31 (23.3) | 2 (0.7) 5 (1.9) 180 (66.7) 83 (30.7) | 3 (4.1) 1 (1.4) 50 (68.5) 19 (26.0) | 0 (0) 1 (1.4) 51 (69.9) 21 (28.8) | ||
| OAT prior admission | 0.364 | 0.748 | ||||
| - no OAT- Vitamin K Antagonist- NOAC | 118 (88.7) 5 (3.8) 10 (7.5) | 220 (81.5) 18 (6.7) 32 (11.9) | 65 (89.0) 4 (5.5) 4 (5.5) | 62 (84.9) 6 (8.2) 5 (6.8) | ||
| Risk factors | ||||||
| Previous stroke | 33 (24.8) | 60 (22.2) | 0.348 | 17 (23.3) | 14 (19.2) | 0.851 |
| Hypertension | 106 (79.7) | 202 (74.8) | 0.241 | 58 (79.5) | 60 (82.2) | 0.834 |
| Diabetes | 38 (28.6) | 65 (24.1) | 0.441 | 19 (26.0) | 21 (28.8) | 0.853 |
| Stroke symptoms | ||||||
| Aphasia | 31 (23.3) | 71 (26.3) | 0.221 | 13 (17.8) | 13 (17.8) | 1.0 |
| Dysarthria | 72 (54.1) | 149 (55.2) | 0.050 | 37 (50.7) | 40 (54.8) | 0.740 |
| Dysphagia | 51 (38.3) | 128 (47.4) | 0.002 | 23 (31.5) | 34 (46.6) | 0.089 |
| Paresis | 77 (57.9) | 154 (57.0) | 0.336 | 39 (53.4) | 28 (38.4) | 0.331 |
| Onset to admission | ||||||
| 0–6 h 6–24 h >24 h unknown | 66 (49.6) 30 (22.6) 16 (12.0) 21 (15.8) | 177 (65.6) 46 (17.0) 10 (3.7) 37 (13.7) | 0.472 0.223 0.002 0.549 | 44 (60.3) 29 (39.7) – – | 43 (58.9) 30 (41.1) – | 0.99 0.99 – – |
| Treatment | ||||||
| Thrombolysis | 44 (33.1) | 45 (16.6) | 0.001 | 30 (41.1) | 37 (50.7) | 0.319 |
| Endovascular treatment– TICI IIB/III | – | 270 (100) 200 (74.1) | – | —- | 100 (100) 55 (75.3) | – |
| Door-to-needle (mean, SD)Door-to-imaging (mean, SD)Door-to-groin (mean, SD) | 21.0 ± 24.1 25.7 ± 38.2 – | 23.9 ± 21.5 20.1 ± 26.8 69.9 ± 87.3 | 0.274 0.842 – | 18.0 ± 17.3 19.4 ± 27.7 – | 23.9 ± 24.9 25.2 ± 33.7 76.2 ± 90.0 | 0.360 0.371 – |
| Length of hospitalization (day, mean, SD) | 10.8 ± 12.5 | 12.1 ± 13.2 | 0.337 | 12.9 ± 15.1 | 12.3 ± 8.8 | 0.773 |
BMT, best medical treatment; EVT, endovascular thrombectomy; IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; mRS, modified rankin scale; OAT, oral anticoagulation treatment; NOAC, novel oral anticoagulant; TICI, thrombolysis in cerebral infarction scale, unless otherwise declared n (%).